Abstract: Recombinant protein expression systems that produce high yields of pure proteins and multi-protein complexes are essential to meet the needs of biologists, biochemists, and structural biologists using X-ray crystallography and cryo-electron microscopy. An ideal expression system for recombinant human proteins is cultured human cells where the correct translation and chaperone machinery are present. However, compared to bacterial expression systems, human cell cultures present several technical challenges to their use as an expression system. We developed a method that utilizes a YFP fusion-tag to generate recombinant proteins using suspension-cultured HEK293F cells. YFP is a dual-function tag that enables direct visualization and fluorescence-based selection of high expressing clones for and rapid purification using a high-stringency, high-affinity anti-GFP/YFP nanobody support. We demonstrate the utility of this system by expressing two large human proteins, TOP2a (340 KDa dimer) and a TOP2b catalytic core (260 KDa dimer). This robustly and reproducibly yields >10 mg/L liter of cell culture using transient expression or 2.5 mg/L using stable expression.
Introduction
Recombinant protein expression in cultured mammalian cells offers advantages over other methods such as E. coli, yeast, or baculovirus-mediated expression in insect cells. Although E. coli expressions systems are a mainstay of recombinant protein expression, eukaryotic proteins often fail to express in this heterologous system. 1 In such cases, a eukaryotic expression system provides an alternative route for recombinant protein expression, where protein folding chaperones, post-translational modifications, and/or sub-cellular location closely mirrors those required for folding of native protein. Yeasts such as S. cerevisiae or K. pastoris (aka P. pastoris) can succeed in expressing human proteins where E. coli fail, but the strength and resilience of the yeast cell wall makes extraction of recombinant protein labor intensive. 2, 3 Insect cells and engineered baculovirus are also routinely employed for large-scale eukaryotic protein expression. 4 However, this requires the initial production of bacmid and high-titer baculovirus prior to large-scale protein expression. An ideal system for expressing recombinant human proteins is cultured human cells where proteins can be expressed in their native environment, in the same organelle as the native protein, and folding can occur in the presence of appropriate chaperones and cofactors. Recombinant protein can also acquire the same post-translational modifications as the native protein, which may be a desirable outcome. Alternatively, cellular localization signals can be modified to redirect recombinant protein to a different cellular location and minimize toxic effects associated with overexpression. The development of human cell lines that grow well in suspension (e.g. HEK293F) and synthetic media that compares favorably to the cost of traditional FBS-supplemented growth media have made large scale growth of mammalian cells feasible. 5 Transient expression of recombinant proteins by transfecting plasmid DNA can be used to express recombinant proteins before toxic effects overwhelm a culture. Establishing human cell lines that constitutively overexpress tagged recombinant protein at high levels provides an alternative means generate recombinant protein, particularly if multiple, repeated preparations are desired. This approach has a trade-off that generation of stable cell lines requires additional preparatory work and is not feasible for toxic proteins. Although either of these approaches are feasible for suspension cultures that can be easily scaled up (>1 L), they require a method to measure recombinant protein expression to optimize yields. Enhanced-green fluorescent protein (GFP) is widely employed as a protein tag for microscopy to observe the cellular location of proteins, and methodologies for delivery and expression of GFP-fusion transgenes in cultured mammalian cell lines are well established. 6 These nanobodies can be synthesized in large quantities using E. coli expression systems and coupled to NHS-activated sepharose resin to generate an efficient anti-GFP/YFP affinity resin. However, the feasibility of using this low-cost reagent for largescale recombinant protein production in mammalian cells has not been assessed. Additionally, the fusion of a fluorescent reporter to the protein of interest could in principal be exploited to monitor selection of highly fluorescent fusion protein expressing clones. However, such fusion of florescence selection and the use of high affinity nanobody based isolation of fluorescent proteins for the high-yield production of recombinant protein has not been rigorously explored.
Here, we describe a procedure for expression of recombinant protein in HEK293F cells using Greenor Yellow-Fluorescent Protein (GFP/YFP) tags that overcomes many of the aforementioned obstacles. We use this method to transiently express YFP-tagged wildtype human Topoisomerase 2a (TOP2a, amino acids 1-1531) and isolate it using anti-GFP/YFP nanobody sepharose with yields of over 10 mg of active recombinant TOP2a per liter of HEK293F cell culture. We also demonstrate the utility of the YFP tag for generating a stable cell line that overexpresses recombinant protein in HEK293F cells using TOP2b core (amino acids 47-1212). Finally, we show that nanobody-sepharose resin can be regenerated and reused many times, similar to other standard low-cost laboratory affinity matrices.
Results

Expression of topoisomerase 2a in HEK293F cells by transient expression
Constitutive overexpression of Type 2 Topoisomerases is toxic for the expressing organism due to altered DNA topology. Expression of full-length human Type 2 topoisomerases (TOP2) in E. coli fails to produce active protein on a scale beyond trace activity, and current published protocols for overexpression of tagless TOP2 in yeast use a lengthy purification protocol. 13, 14 To develop a more efficient method of producing recombinant TOP2, we sought to express human TOP2 alpha (TOP2a) in HEK293F cells. 15 Our attempts to produce cell lines that stably overexpress human TOP2a at sufficient levels for recombinant protein production were unsuccessful, likely due to toxicity. Although removal of the nuclear localization signal (NLS) might alleviate toxicity, we sought to obtain recombinant protein that matches (as closely as possible) the native protein. Therefore, we evaluated transient overexpression in HEK293F cells using transfected plasmid DNA as a means for producing TOP2a.
We designed a plasmid that encodes YFP with a TEV protease cleavage site fused to its C-terminus, followed by TOP2a [ Fig. 1(A) , see Materials and Methods]. TEV protease tolerates a methionine residue in the P1 0 position, 16 so we designed an expression construct that places the TOP2a methionine-start codon in this position. TEV cleavage of this construct yields TOP2a with an N-terminus that corresponds precisely to the native N-terminal methionine. In adherent HEK293F cells this construct expresses well and produces a visible nuclear YFP signal [ Fig. 1(B) ], so we sought to scale-up expression of this construct. To transfect this plasmid into HEK293F cells we used polyethylenimine (PEI), which is a cost-effective reagent for transfection of suspension cell culture. A number of recent publications have reviewed or described methodologies that achieve transfection efficiencies comparable to those obtained with cationic lipid transfection reagents. [17] [18] [19] [20] We tested a variation of the procedure described by Longo et al., 21 and we routinely achieve transfection efficiencies over 60%.
To optimize transfection conditions, we titrated the concentration of PEI (2-8 lg/mL) and utilized the fluorescence of the YFP-tag to measure expression of YFP-TOP2a. 22 In this way, we were able to evaluate Fig. 1(F) ]. After optimizing the PEI concentration, we also titrated the amount of transfected plasmid DNA, and found that 3 lg/mL was an optimal amount. From this, we concluded that the optimal transfection conditions used 3 lg/mL of PEI with 3 lg/mL of plasmid DNA (i.e. a 1:1 mass ratio with plasmid DNA), followed by growth for 3 days before harvesting cells.
The utility of a YFP-tag as an expression reporter can be complemented by its use as a protein-purification tag. Several anti-GFP nanobodies have been identified that bind GFP or YFP with picomolar affinity and high specificity, and can be chemically crosslinked to sepharose to form a GFP/ YFP binding resin 11, 12 [ Fig. 2(A) ]. We chose to use a nanobody that has been reported to enhance GFP fluorescence, 11 as the enhanced fluorescence could aid in visualization of protein bound to sepharoseconjucated nanobody. Such resins have been shown to quantitatively bind GFP proteins after a single pass of lysate and retain GFP even in the presence of high salt (2 M NaCl) or high temperature (658C), 12 suggesting that upon scale-up, this resin would be a suitable means to rapidly isolate large quantities of YFP-tagged TOP2a under a wide range of buffer conditions. To assess the yield of TOP2a, we transfected a 400 mL culture of HEK293F cells at a density of 3 3 10 6 cells mL 21 [ Fig. 2 In principle, human proteins that are expressed in human cells may remain associated to their native binding partners, so extensive washing with high salts was used to minimize co-purifying contaminants. TOP2a was eluted from the resin by quickly passing wash buffer with TEV protease over the column, which is then stoppered and incubated at 48C overnight to allow TEV protease to cleave TOP2a from the resin-bound YFP. The TEV cleavage reaction was monitored by analyzing a sample of resin by SDS-PAGE, which showed the TEV reaction was nearly complete after 16 h [ The final, purified TOP2a runs as a single band on an SDS-PAGE and is >99% pure, with minor contaminants or proteolysis fragments visible only upon loading of extremely high amounts of protein [ Fig.  3(C) ]. Subsequently, TOP2a was buffer-exchanged into a high-salt buffer containing 25% glycerol, and was stable after storage at 2808C for over 6 months. Yields of 10-20 mg purified TOP2a were consistently obtained from 1 L cultures, and the protein shows DNA decatenation activity similar to enzyme purchased from a commercial source, requiring 0.5 nM TOP2a to decatenate 50% of kinetoplast DNA in 1 h [ Fig. 3(D,E) ], which is comparable to values reported for other TOP2 homologs. 23, 24 Expression of topoisomerase 2b (47-1212) in HEK293F cells by stable integration of an expression cassette Like for TOP2a, we failed in establishing stable cells lines that robustly over-express full-length TOP2b. We sought to mitigate the toxicity of overexpressed TOP2 and evaluate the ability of HEK293F cells to generate recombinant protein from a genomic expression cassette. We designed an expression construct for a 130 KDa TOP2b fragment (aa 47-1212) that lacks the N-and C-terminal flexible regions as well as the NLS. By removing the NLS, overexpressed TOP2 is not transported to the nucleus, similar to truncation of the yeast Top2 enzyme [ Fig. 4(A) ]. We compared expression and purification from transiently transfected vectors encoding fulllength and truncated YFP-TOP2b constructs (Supporting Information, Fig. S3 ). While the truncated cytoplasmic form has slightly increased yields, we also could purify milligram quantities of nuclear YFP-TOP2b-FL when transiently transfected. These results are consistent with low yields from stable expression system being due to limits of stable overexpression of the full-length protein rather than stability of the expressed proteins or cytoplasmic versus nuclear localization.
Populations of HEK293F cells expressing moderate or high levels of YFP-TOP2b (47-1212) were isolated by FACS [ Fig. 4(B) ]. These cells have robust growth that is similar to those of wildtype cells (doubling time of 15.3 h for HEK293F vs. 15.5 h for YFP-TOP2b cells). For YFP-TOP2b (47-1212) which localizes to the cytoplasm [ Fig. 4(A) ], expression is stable in solution-phase growth, and both YFP expression levels and yields of recombinant protein were stable over the course of several weeks, even in the absence of antibiotic selection.
To test if fluorescence selection can be predictive of purified protein yields, we performed expression tests to compare TOP2b (47-1212) protein yields from medium and high YFP-fluorescing cell populations. We found that the higher YFP-fluorescing cells produced approximately twice as much TOP2b as the medium YFP fluorescing cells [ Fig. 4(C,D) ], indicating that fluorescence from the YFP-tag is a suitable indicator of protein expression levels in stable cell lines. To assess the yield of TOP2b from these cells we performed purifications from 1 L cultures, using the same procedure implemented for TOP2a. Although the TEV eluted protein is quite pure, TOP2b (47-1212) still retains dimerization interfaces, and a doublet of 170 and 180 KDa bands indicates the presence of some copurifying heterodimers with endogenous TOP2a and TOP2b [ Fig. 4(C) ]. Sequential ion exchange chromatography [ Fig. 4(E) ] and size-exclusion chromatography [ Fig. 4(F) ] removed the endogenous TOP2a and TOP2b and other minor contaminants. The final protein is highly pure, showing a 130 KDa band on an SDS-PAGE [ Fig. 4(G) ]. Yields of 2.5 mg of purified TOP2b (47-1212) were consistently obtained from 1 L cultures, which was lower than that generated by transfection, but has the advantage that preparation and transfection of plasmid DNA is not required. The final, purified TOP2b shows DNA decatenation activity comparable to that reported for TOP2a or TOP2 prepared by other methods, requiring 0.5 nM TOP2b to decatenate 50% of kinetoplast DNA in 1 h [ Fig.  4(H) ].
Reusability of anti-GFP/YFP sepharose
The anti-GFP nanobody binds very tightly to GFP/ YFP, and protein cannot be removed using mild conditions. To regenerate the resin after use, we used a low pH wash (0.1 M glycine pH 2) to remove YFP and any remaining uncleaved YFP-TOP2a from the resin. In this way, we have been able to reuse this resin 20 times with no noticeable loss of binding capacity [ Fig. 4(I) ], similar to other commonly used affinity matrices such as amylose-sepharose, glutathione-sepharose, or Ni-NTA.
Discussion
Here, we describe a method for expressing recombinant protein in human cells using YFP (or GFP) as an affinity tag that helps to overcome a number of technical challenges associated with protein expression in cultured human cells. Direct visualization of the fluorescence from YFP is a simple and rapid means of measuring protein expression. HEK293F cells grown in suspension cultures can be transfected using lowcost PEI and expression conditions can be adjusted to maximize YFP fluorescence. Thus, a transfection and expression protocol can be developed without using labor-intensive means such as western blotting or pilot-scale protein purification trials, and problems with plasmid DNA substrates or transfection protocols can be identified and corrected before investing resources in large-scale growth.
Direct visualization of recombinant protein expression greatly facilitates the establishment of cell lines that stably express tagged protein. The highest-expression pool from a population of transgene integrants can be selected in a single step using fluorescent-activated cell sorting (FACS), without the need to select and screen single clones. Furthermore, the transgene toxicity can be gauged early on in the process of generating stable integrants. A lack of antibiotic resistant cells that express YFP/ GFP with the expected cellular localization suggests toxicity caused by the YFP/GFP fusion.
An important feature of the anti-GFP/YFP nanobody resin is the combination of tight binding with high specificity, combined with specific elution by TEV protease, yielding recombinant protein with low levels of contaminants, which is advantageous for isolation of proteins expressed in human cells where expression levels may not be very high. When expressing YFPtagged human proteins in human cells, endogenous binding partners can copurify with a YFP tagged protein-which may or may not be the desired outcome. The robust nanobody-YFP interaction is relatively insensitive to buffer concentrations 12 and accordingly, buffer conditions can be adjusted to either preserve or disrupt protein binding partner interactions. Nanobody stability is also important for regenerating the resin for reuse. While lowering the pH to 2 is sufficient to elute YFP or GFP, in cases where precipitated protein or other unwanted components have contaminated the resin harsher washes such as those containing 0.5% SDS 26 can be used to clean the resin.
Furthermore, the same GFP-or YFP-tagged construct used for small scale proteomics analysis, assessment of post-translational modifications, 15 ChIP, 27 and can be scaled-up to produce recombinant protein by incorporating a site-specific protease site between the YFP and the tagged recombinant protein.
The YFP affinity tag procedure described herein can be used with other means of delivering DNA, such as cationic lipid transfection reagents or engineered viral gene delivery, where conditions for transfection or infection may need to be optimized. Furthermore, since the anti-GFP/YFP nanobody is specific for these fluorescent proteins, 12 co-expression with another tagged protein (i.e. monomeric red fluorescent protein) could allow for simultaneous detection of the individual proteins and optimization of expression levels. Altogether, the benefits of expressing YFPtagged recombinant proteins overcomes key challenges of expressing recombinant proteins in human cells, and present a straightforward approach to generating recombinant proteins. Anti-GFP nanobody sepharose production DNA encoding the anti-GFP enhancer nanobody (11) with a C-terminal His6 tag codon-optimized for expression in E. coli was synthesized (Atum; formerly DNA 2.0; sequence: atggcacaagtccaactggtagag agcggcggcgccctggtacaaccgggtggttccctgcgtctgtcttgtgcag ccagcggttttccggtgaatcgctatagcatgcgttggtaccgtcaggcgc caggcaaagagcgtgaatgggttgcgggcatgagctcggctggtgacc gtagctcctatgaggacagcgtcaaaggtcgcttcacgatcagccgtga cgatgcgcgcaacaccgtttacttgcagatgaacagcctgaagccgga agataccgcggtttactactgcaatgtgaacgttggtttcgaatattgg ggccagggtacccaggtcacggtgagcagccaccatcatcaccaccac) and cloned behind the T7 promoter in pJ414. The nanobody was expressed in BL21-AI cells (Invitrogen) using 0.02% arabinose induction at 188C overnight in LB media. Cells were pelleted by centrifugation, then frozen at 2808C until use. Pellets were thawed in 40 mL of lysis buffer (B-Per (Pierce) containing 18 mM Imidazole, 18 mM BME, 1 M NaCl, EDTA free Complete protease tablets (Roche), and 0.5 U of Benzonase), incubated for 20 min at RT, then sonicated on ice with three cycles of 30 s max output with 10-min cooling periods. Insoluble debris was removed by centrifugation at 28,000g for 30 min, and soluble lysate was run over a column with 10 mL Ni-NTA sepharose (Qiagen) equilibrated in wash buffer (50 mM HEPES pH 7.5, 0.5 M NaCl, 20 mM Imidazole), washed with 100 mL wash buffer, then eluted with a step gradient of imidazole (50, 100, 200, 300 mM imidazole) in wash buffer. Fractions containing the nanobody were identified by SDS-PAGE, pooled, and dialyzed against 50 mM HEPES pH 7.5 containing 50 mM NaCl. The dialyzed sample was then passed over a 5 mL HiTrap Q column (GE Life Sciences). Virtually all the remaining impurities bound to the HiTrap column while the nanobody flowed through. Purified anti-GFP nanobody was coupled to NHSactivated Sepharose 4 fast flow (GE Healthcare) as per manufacturer's directions. Briefly, a solution of 10 mg mL 21 anti-GFP nanobody was prepared just prior to use. A ratio of 2:1 nanobody solution to NHSactivated Sepharose slurry was incubated overnight at 48C for coupling of the anti-GFP nanobody to the Sepharose. The next day, the resin was washed with 10 column volumes of blocking buffer (0.1 M Tris pH 8.0) to remove unbound nanobody, then incubated for a further 2 h at room temperature to quench any unreacted NHS sites. Once blocking was complete, the sepharose was washed with six cycles of wash buffers (buffer 1: 0.1 M Tris, 0.5 M NaCl pH 8.0, and buffer 2: 0.1 M Na Acetate, 0.5 M NaCl pH 4.0). The anti-GFP Sepharose was then equilibrated in storage buffer (10 mM Tris, 150 mM NaCl) and stored until use at 48C. An aliquot of each batch of anti-GFP/YFP sepharose was tested and found to bind 0.5 mg recombinant GFP per mL of resin. The anti-GFP nanobody binds very tightly to GFP/YFP, and protein cannot be removed using mild conditions. To regenerate the resin after use, we used a low pH wash to remove YFP and any remaining uncleaved YFP-TOP2a from the resin. In this way, we have been able to reuse this resin 20 times with no noticeable loss of binding capacity, similar to other commonly used affinity matrices such as amylosesepharose, glutathione-sepharose, or Ni-NTA. HEK293F cells were pelleted and resuspended in 20 mL Freestyle media, then grown at 378C for 15 min. The transfection mix was prepared as followed: to 1 mL Freestyle media was added the appropriate amount of PEI, and to 1 mL Freestyle was added 60 lg (or otherwise as indicated) plasmid DNA. The two 1 mL solutions were mixed together, incubated for 60 s at room temperature, then added to the 20 mL cell cultures. After the indicated times, samples of the culture were counted using a Cellometer 2000 Auto (Nexelom). A 4 s exposure was used to determine the % YFP positive cells and a 1 s exposure was used to measure the YFP intensity without overloading the camera. Additional media was added to the cultures: 20 mL on days 1 and 2, 40 mL on days 3 and 4 to maintain cell growth.
Methods
Plasmid
Microscopy
Production-scale culture growth
For transfection of production-scale cultures, 1.2 3 10 9 HEK293F cells were pelleted by centrifugation, resuspended in 400 mL pre-warmed Freestyle media in a 3 L flask with a vented cap (Genemate), and incubated for 15 min before transfection. YFPTOP2a plasmid DNA (1.2 mg) was added to 5 mL Freestyle media, and 1.2 mg PEI was added to 35 mL Freestyle. The two solutions were mixed together and incubated for 30 s, then added to the 400 mL culture of HEK293F cells. After 24 h, 400 mL Freestyle was added to the culture, and after 48 h another 200 mL Freestyle media was added to maintain cell growth. After 72 h, cells were pelleted by centrifugation at 400g for 10 min, resuspended in 80 mL PBS, and pelleted again at 500g before proceeding with cell lysis. For production of TOP2b (47-1212) from stable expression HEK293F cells, the desired culture volume was grown to a density of 2.5-3.0 3 10 9 cells per mL, then pelleted by centrifugation at 400g for 10 min, resuspended in 80 mL PBS, and pelleted again at 500g before proceeding with cell lysis.
Cell lysis and purification of TOP2a and TOP2b
HEK293F cell pellets (12 mL from 1L culture) were lysed in 36 mL lysis buffer (50 mM TRIS pH 8.0, 600 mM NaCl, 0.5% (v/v) NP-40 substitute (Sigma), and 1 mM TCEP) supplemented with complete-EDTA free protease inhibitor cocktail (Roche), and sonicated with three cycles of 5 s sonication using a Branson sonicator set to 55% power, followed by 30 s cooling periods. Crude lysate was centrifuged at 15,000g for 10 min, then passed over a column with pre-equilibrated anti-GFP/YFP sepharose resin. The color of the resin was monitored visually, and additional resin was used if the resin became saturated. The resin was washed twice with lysis buffer, four times with wash buffer (50 mM TRIS pH 8.0, 400 mM NaCl, 0.1% (v/v) NP-40 substitute, and 1 mM TCEP), and twice with low salt wash buffer (20 mM TRIS pH 8.0, 200 mM NaCl, 0.1% (v/v) TWEEN-20, and 1 mM TCEP). Following these washes, the resin was washed quickly into TEV elution buffer (low salt wash with 20 lg mL 21 TEV protease), then stoppered and incubated overnight at 48C. TOP2 was eluted the next day by washing the resin with size-exclusion buffer (20 mM TRIS pH 7.5, 500 mM NaCl, 1 mM TCEP).
FPLC purification of TOP2a and TOP2b
Anti-GFP/YFP sepharose eluate was concentrated to 2 mL volume by ultrafiltration (Amicon) and run on a Superdex200 16/60 column (GE) in size-exclusion buffer. Fractions containing TOP2a were pooled and diluted in 10 volumes of low salt buffer (20 mM TRIS pH 7.5, 1 mM DTT), loaded onto a 6 mL SOURCE 15S column (GE Healthcare), and eluted with a linear gradient of 0%-50% high salt buffer (20 mM TRIS pH 7.5, 1 M NaCl). Fractions containing TOP2a were pooled, concentrated by ultrafiltration, and buffer exchanged into TOP2 storage buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 1 mM TCEP, and 25% (v/v) glycerol). Protein aliquots were stored long term (>6 months) at 2808C or short term (<1 month) at 2208C.
Assay of TOP2a
TOP2a DNA decatenation activity was measured in 10 lL reactions containing 50 mM TRIS pH 8.0, 100 mM NaCl, 5 mM MgCl 2 , 2 mM ATP, 0.5 mM DTT, 0.2 mM TCEP, 0.25 mg mL 21 BSA, 5% (v/v) glycerol, 250 ng kinetoplast DNA (Topogen), and the indicated concentration of TOP2a. Reactions were incubated for 60 min at 378C then run on a 0.9% (w/v) TBE-agarose gel.
Regeneration of anti-YFP/GFP sepharose
After TEV elution of TOP2a, resin was washed once with water, three times with three column volumes of 0.1 M glycine pH 2.0, then three column volumes of Lysis buffer. The loss of yellow color served as a visual indicator of YFP removal.
